JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
Among patients with relapsing #MultipleSclerosis, earlier and continuous ocrelizumab treatment was associated with better long-term relapse and disability control than delayed initiation after interferon beta-1a.
